These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 22459199)
1. Metastatic pancreatic neuroendocrine tumors (pNET): placing current findings into perspective. Phan AT Cancer Treat Rev; 2013 Feb; 39(1):3-9. PubMed ID: 22459199 [TBL] [Abstract][Full Text] [Related]
2. Everolimus: a new treatment option for advanced pancreatic neuroendocrine tumors. Thompson LA; Kim M; Wenger SD; O'Bryant CL Ann Pharmacother; 2012 Sep; 46(9):1212-9. PubMed ID: 22947595 [TBL] [Abstract][Full Text] [Related]
3. Pancreatic neuroendocrine tumors: entering a new era. Oberstein PE; Remotti H; Saif MW; Libutti SK JOP; 2012 Mar; 13(2):169-73. PubMed ID: 22406593 [TBL] [Abstract][Full Text] [Related]
4. Therapeutic strategies for advanced neuroendocrine carcinomas of jejunum/ileum and pancreatic origin. Auernhammer CJ; Göke B Gut; 2011 Jul; 60(7):1009-21. PubMed ID: 21378384 [TBL] [Abstract][Full Text] [Related]
5. Pancreatic neuroendocrine tumors: a comprehensive review. Zhou C; Zhang J; Zheng Y; Zhu Z Int J Cancer; 2012 Sep; 131(5):1013-22. PubMed ID: 22437917 [TBL] [Abstract][Full Text] [Related]
6. Everolimus for the treatment of pancreatic neuroendocrine tumors. Feldmann G; Bisht S; Schütte U; Haarmann J; Brossart P Expert Opin Pharmacother; 2012 Oct; 13(14):2073-84. PubMed ID: 22873789 [TBL] [Abstract][Full Text] [Related]
7. Novel agents in the treatment of unresectable neuroendocrine tumors. Highlights from the "2011 ASCO Annual Meeting". Chicago, IL, USA; June 3-7, 2011. Oberstein PE; Saif MW JOP; 2011 Jul; 12(4):358-61. PubMed ID: 21737896 [TBL] [Abstract][Full Text] [Related]
10. From targets to treatments: a review of molecular targets in pancreatic neuroendocrine tumors. Wiedenmann B; Pavel M; Kos-Kudla B Neuroendocrinology; 2011; 94(3):177-90. PubMed ID: 21893937 [TBL] [Abstract][Full Text] [Related]
11. Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors. Chan HY; Grossman AB; Bukowski RM Adv Ther; 2010 Aug; 27(8):495-511. PubMed ID: 20623346 [TBL] [Abstract][Full Text] [Related]
12. Update on novel therapies for pancreatic neuroendocrine tumors. Oberstein PE; Saif MW JOP; 2012 Jul; 13(4):372-5. PubMed ID: 22797392 [TBL] [Abstract][Full Text] [Related]
13. Neuroendocrine tumors of the pancreas. Ehehalt F; Saeger HD; Schmidt CM; Grützmann R Oncologist; 2009 May; 14(5):456-67. PubMed ID: 19411317 [TBL] [Abstract][Full Text] [Related]
14. Role of everolimus in pancreatic neuroendocrine tumors. Goldstein R; Meyer T Expert Rev Anticancer Ther; 2011 Nov; 11(11):1653-65. PubMed ID: 21932937 [TBL] [Abstract][Full Text] [Related]
15. Radioembolization in the treatment of neuroendocrine tumors of the pancreas. John PK; Saif MW JOP; 2014 Jul; 15(4):332-4. PubMed ID: 25076336 [TBL] [Abstract][Full Text] [Related]
16. [Recent advances in treatment of pancreatic neuroendocrine tumors]. Imamura M Nihon Geka Gakkai Zasshi; 2008 May; 109(3):143-6. PubMed ID: 18536317 [TBL] [Abstract][Full Text] [Related]
17. Neuroendocrine tumors of the digestive tract: impact of new classifications and new agents on therapeutic approaches. Oberg K Curr Opin Oncol; 2012 Jul; 24(4):433-40. PubMed ID: 22510940 [TBL] [Abstract][Full Text] [Related]
18. [Chemotherapy for GI and pancreatic NETs]. Doi T Gan To Kagaku Ryoho; 2013 Jul; 40(7):838-42. PubMed ID: 23863723 [TBL] [Abstract][Full Text] [Related]